Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

Evercore ISI initiated coverage on MindMed shares (NASDAQ:MNMD) with an Outperform rating and a price target of $23.00, well ...

Syndax Pharmaceuticals , a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, ...

ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

And, in March 2024, the FDA granted breakthrough designation for Mind Medicines (MindMed), MM120, (LSD D-tartrate) for the treatment of generalised anxiety disorder (GAD). In April 2024 ...

Another notable event for the field occurred in March 2024, as MindMed received breakthrough designation from the FDA for its MM120 (lysergide d-tartrate) potential therapy. The drug is a ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Mind Medicine (MNMD – Research Report). The associated price ...